Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

The Cellecutix share price jumped when Brilacidin QIDP designation was announced on December 8, 2014
http://cellceutix.com/cellceutix-antibiotic-brilacidin-receives-qidp-designation-from-fda/#sthash.IDhXbuGI.dpbs

It can be seen in the following chart.


Without the Brilacidin acquisition and trial results the shares would be priced much lower as investors tired of waiting on Kevetrin results.

As Brilacidin has been moving forward the share price has been moving forward. Brilacidin is further along in the trial process and has shown successful results.

Kevetrin is showing promise, but, the market won't price it in until trial results are in. It is difficult to be sure how Kevetrin is priced in, but, Brilacidin has substantially derisked this investment. I don't view it as much of a gamble even though nothing is guaranteed in the market.





In Reply to 'p53'
Caution required on Kevetrin certainly. At this point just searching for correct dosing,with hope to go on, some science, but mostly hopes. It is still so early.

Let's take the last published report about the vanishing spleen lesion. Lower in the article it says the patient's CA125(tumor marker) continued to rise, suggesting that change in ascites and spleen lesion was telling only part of the story.

Many here are gambling that there will be a payoff, and the stock has risen for quite a while.It is surely a gamble though.

Take away Kevetrin and how much will B and Prurisol be worth? Hard to be sure.